RQ Biotechnology Limited
PrivateLast Round
Series A
Jun 24, 2026
Total Funding Raised
$230M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
RQ Biotechnology Limited is a biotechnology company that develops potent, broad-spectrum monoclonal antibodies to provide passive immunization against viral infections for vulnerable populations.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RQ Biotechnology Limited Comparables
Compare RQ Biotechnology Limited with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NorthLinks Bio | 74% | |
| AstraZeneca | 71% | |
| Merck & Co., Inc. | 68% |
RQ Biotechnology Limited Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 24, 2026 | ||||
| Series A | Jun 24, 2024 |
Key People
Founding team and executive leadership
RQ Biotechnology Limited Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series A |
| Forbion | Series A |
| Oxford Science Enterprises | Series A |
| Monograph Capital | Series A |
| University of Oxford | Series A |
| Frazier Life Sciences | Series A |
| LifeArc Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 12, 2026
Open roles increased to 9, 47% of headcount.
- Oct 1, 2026
Open roles increased to 6, representing 32% of headcount.
Recent news
Latest coverage and updates
- hiresOct 6, 2026
RQ Biotechnology Ltd. hires Debra Nevin, Ph.D., as Vice President, Head of CMC
- hiresOct 6, 2026
RQ Biotechnology Ltd. appoints Vicky Wheeler as Senior Director, Head of Programme Management on Oct 6th '26
- hiresOct 6, 2026
RQ Biotechnology Ltd. appoints Gavin Koh as Chief Medical Officer in United Kingdom on Oct 6th '26
- hiresOct 6, 2026
RQ Biotechnology Ltd. hires Brad Norton as Vice President, Head of Clinical Operations in Oct '26
- receives_financingOct 6, 2026
RQ Biotechnology Ltd. receives $115M Series A financing, announced in Jun '26, to support the clinical development of RQB01.
RQ Biotechnology Limited Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about RQ Biotechnology Limited's valuation, stock price, and market status.
Is RQ Biotechnology Limited a public or private company?
RQ Biotechnology Limited is a private company.
What is the current stock price of RQ Biotechnology Limited?
RQ Biotechnology Limited is a private company, so its shares have no public market price. Caplight tracks RQ Biotechnology Limited's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RQ Biotechnology Limited worth (valuation)?
Valuation information for RQ Biotechnology Limited is not publicly available.
Can I buy RQ Biotechnology Limited stock?
RQ Biotechnology Limited shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RQ Biotechnology Limited's last funding round?
RQ Biotechnology Limited's most recent funding round was Series A on June 24, 2026.
Who are the main investors in RQ Biotechnology Limited?
Key investors in RQ Biotechnology Limited include Frazier Life Sciences.
Will RQ Biotechnology Limited IPO soon?
No public IPO plans have been announced for RQ Biotechnology Limited.
How can I track RQ Biotechnology Limited secondary market activity?
Caplight tracks bids, offers, and trades in RQ Biotechnology Limited's shares on secondary markets.